Pen Needles

Pen Needles

Global Pen Needles Market to Reach $3.6 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Pen Needles estimated at US$2 Billion in the year 2020, is projected to reach a revised size of US$3.6 Billion by 2027, growing at aCAGR of 8.7% over the period 2020-2027. Standard, one of the segments analyzed in the report, is projected to record 6.9% CAGR and reach US$2.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Safety segment is readjusted to a revised 11.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $657.4 Million, While China is Forecast to Grow at 9.7% CAGR
The Pen Needles market in the U.S. is estimated at US$657.4 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$278.9 Million by the year 2027 trailing a CAGR of 9.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.4% and 7.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR.

Select Competitors (Total 63 Featured) -

  • AdvaCare Pharma
  • Allison Medical Inc.
  • ARKRAY, Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Berpu Medical Technology Co., Ltd.
  • GlucoRx Limited
  • Hindustan Syringes & Medical Devices Ltd.
  • HTL-STREFA S.A.
  • Iyon Saglik Medical
  • Links Medical Products, Inc.
  • MHC Medical Products, LLC
  • Montméd Inc.
  • Nipro Corporation
  • Novo Nordisk
  • Owen Mumford Ltd.
  • Promisemed Medical Devices Inc.
  • Simple Diagnostics
  • Terumo Europe NV
  • Trividia Health, Inc.
  • UltiMed, Inc.
  • Van Heek Medical
  • Vogt Medical Vertrieb GmbH
  • Ypsomed AG
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Impact of COVID-19 and a Looming Global Recession
The Never-Ending “Race” Between the Virus & Vaccines Continues. Amidst this Chaotic Battle, Where is the World Economy Heading Now & Beyond?
Omicron Variant Brings Back Memories & Fears of the Worst Part of the 2020 Pandemic
EXHIBIT 1: Time is of Essence! What We Know So Far – “Vaccine Efficiency Against New Strains”
With New Strains Emerging at an Alarming Rate, Focus Shifts to Booster Doses & Vaccine Tweaking. But How Practical Is It to Implement Them?
EXHIBIT 2: With Vaccinated Population Showing Signs of Declining Clinical Protection, Booster Doses Are Emerging Into a Necessity to Restore Vaccine Effectiveness: Number of Booster Doses Administered Per 100 People by Country as of December 2021
How Healthcare Has Been Impacted & Beyond COVID-19 What’s In Store for Healthcare?
EXHIBIT 3: Missed Cancer Diagnosis in U.S. as of June 2020
EXHIBIT 4: % Reduction in OR Volumes in the US: Mar 2020-July 2020
EXHIBIT 5: Cumulative Surgery Cancellations Worldwide (In Million)
EXHIBIT 6: With the COVID-19 Pandemic Exposing Global Healthcare Unpreparedness, There is Increasing Policy Led Focus on Rebooting Health Systems Worldwide: Current & Required Healthcare Spending as % of GDP
COVID-19 and Elective Surgeries
COVID-19 Impact on Pen Needles Market
Competition
EXHIBIT 7: Pen Needles – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Market Players Worldwide in 2022 (E)
Needles: A Prelude
Types of Needles
An Insight into Pen Needles
Pen Needles for Insulin Injection
Global Market Analysis and Prospects
Global Pen Needles Market Set for a Rapid Growth
Standard Pen Needles Dominate, Safety Pen Needles to Witness Fastest Growth
Emerging Markets: Focal Point for Future Growth
Competitive Landscape
Top Pen Needle Products
Recent Market Activity
WORLD BRANDS
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rise in Diabetic Population Continues to Drives Demand for Pen Needles
EXHIBIT 8: World Diabetes and Population Statistics (2019, 2030 & 2045)
EXHIBIT 9: Global Prevalence of Diabetes: Number of Adults Diagnosed with Diabetes (in Million) by Gender for 2019, 2030 and 2045
EXHIBIT 10: World Diabetes Prevalence (2000-2019)
EXHIBIT 11: Top 10 Countries with Highest Number of Adults Diagnosed with Diabetes (in Million) for 2019 and 2045
EXHIBIT 12: Global Diabetes Mellitus Population Breakdown by Geographic Region: 2019, 2030 and 2045?
Diabetes Emerges as One of the Leading Causes of Mortality
EXHIBIT 13: Diabetes-Related Deaths as % of Total Deaths in Below 60 Years Population by Region: 2019
Growing Prevalence of Chronic Diseases Drive the Demand for Pen Needles
EXHIBIT 14: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT 15: Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2018
EXHIBIT 16: Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
High Risk of Diabetes in the Fast Expanding Aging Population Benefit Market Expansion
EXHIBIT 17: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
EXHIBIT 18: Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
Pen Needles Gain Traction as Insulin Pens Rise in Popularity for Administering Insulin
Smart Insulin Pens: A Growing Area of Interest
Increasing Role of Self-Injection Devices in Diabetes Management
Needle-Free Alternatives: A Growing Threat
Innovative Technologies Revolutionize Pen Needles Market
Advancements in Insulin Delivery Methods Drive the Demand for Pen Needles
Advancements in Pen Needle Technology
Droplet Micron Insulin Needle Represents Innovation in the Diabetes Supply Market
MACRO GROWTH DRIVERS
Increasing Healthcare Expenditure Aids Pen Drives Market Growth
EXHIBIT 19: World Healthcare Expenditure (In US$ Trillion) for the Years for 2017, 2019, 2021, and 2023
Increasing Obesity Levels Underpins Market Growth
EXHIBIT 20: Average Per Capita Annual Health Expenditure (In US$) due to Obesity
EXHIBIT 21: Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
Rising Demand for Biosimilar Drugs Propel the Market for Pen Needles
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 2: World Historic Review for Pen Needles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 3: World 15-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027
TABLE 4: World Recent Past, Current & Future Analysis for Standard by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 5: World Historic Review for Standard by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 6: World 15-Year Perspective for Standard by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 7: World Recent Past, Current & Future Analysis for Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 8: World Historic Review for Safety by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 9: World 15-Year Perspective for Safety by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 10: World Recent Past, Current & Future Analysis for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 11: World Historic Review for Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 12: World 15-Year Perspective for Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 13: World Recent Past, Current & Future Analysis for Glucagon-Like Peptide-1 (GLP-1) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 14: World Historic Review for Glucagon-Like Peptide-1 (GLP-1) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 15: World 15-Year Perspective for Glucagon-Like Peptide-1 (GLP-1) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
TABLE 16: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 17: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 18: World 15-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
TABLE 19: USA Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 20: USA Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 21: USA 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 22: USA Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 23: USA Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 24: USA 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
CANADA
TABLE 25: Canada Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 26: Canada Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 27: Canada 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 28: Canada Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 29: Canada Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 30: Canada 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
JAPAN
TABLE 31: Japan Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 32: Japan Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 33: Japan 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 34: Japan Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 35: Japan Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 36: Japan 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
CHINA
TABLE 37: China Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 38: China Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 39: China 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 40: China Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 41: China Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 42: China 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
EUROPE
TABLE 43: Europe Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 44: Europe Historic Review for Pen Needles by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 45: Europe 15-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027
TABLE 46: Europe Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 47: Europe Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 48: Europe 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 49: Europe Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 50: Europe Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 51: Europe 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
FRANCE
TABLE 52: France Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 53: France Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 54: France 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 55: France Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 56: France Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 57: France 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
GERMANY
TABLE 58: Germany Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 59: Germany Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 60: Germany 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 61: Germany Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 62: Germany Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 63: Germany 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
ITALY
TABLE 64: Italy Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 65: Italy Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 66: Italy 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 67: Italy Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 68: Italy Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 69: Italy 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
UNITED KINGDOM
TABLE 70: UK Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 71: UK Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 72: UK 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 73: UK Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 74: UK Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 75: UK 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
SPAIN
TABLE 76: Spain Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 77: Spain Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 78: Spain 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 79: Spain Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 80: Spain Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 81: Spain 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
RUSSIA
TABLE 82: Russia Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 83: Russia Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 84: Russia 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 85: Russia Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 86: Russia Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 87: Russia 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
REST OF EUROPE
TABLE 88: Rest of Europe Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 89: Rest of Europe Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 90: Rest of Europe 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 91: Rest of Europe Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 92: Rest of Europe Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 93: Rest of Europe 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
ASIA-PACIFIC
TABLE 94: Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 95: Asia-Pacific Historic Review for Pen Needles by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 96: Asia-Pacific 15-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027
TABLE 97: Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 98: Asia-Pacific Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 99: Asia-Pacific 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 100: Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 101: Asia-Pacific Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 102: Asia-Pacific 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
AUSTRALIA
TABLE 103: Australia Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 104: Australia Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 105: Australia 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 106: Australia Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 107: Australia Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 108: Australia 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
INDIA
TABLE 109: India Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 110: India Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 111: India 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 112: India Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 113: India Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 114: India 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
SOUTH KOREA
TABLE 115: South Korea Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 116: South Korea Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 117: South Korea 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 118: South Korea Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 119: South Korea Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 120: South Korea 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
REST OF ASIA-PACIFIC
TABLE 121: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 122: Rest of Asia-Pacific Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 123: Rest of Asia-Pacific 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 124: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 125: Rest of Asia-Pacific Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 126: Rest of Asia-Pacific 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
LATIN AMERICA
TABLE 127: Latin America Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 128: Latin America Historic Review for Pen Needles by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 129: Latin America 15-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2021 & 2027
TABLE 130: Latin America Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 131: Latin America Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 132: Latin America 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 133: Latin America Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 134: Latin America Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 135: Latin America 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
ARGENTINA
TABLE 136: Argentina Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 137: Argentina Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 138: Argentina 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 139: Argentina Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 140: Argentina Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 141: Argentina 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
BRAZIL
TABLE 142: Brazil Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 143: Brazil Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 144: Brazil 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 145: Brazil Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 146: Brazil Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 147: Brazil 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
MEXICO
TABLE 148: Mexico Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 149: Mexico Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 150: Mexico 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 151: Mexico Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 152: Mexico Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 153: Mexico 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
REST OF LATIN AMERICA
TABLE 154: Rest of Latin America Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 155: Rest of Latin America Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 156: Rest of Latin America 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 157: Rest of Latin America Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 158: Rest of Latin America Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 159: Rest of Latin America 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
MIDDLE EAST
TABLE 160: Middle East Recent Past, Current & Future Analysis for Pen Needles by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 161: Middle East Historic Review for Pen Needles by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 162: Middle East 15-Year Perspective for Pen Needles by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2021 & 2027
TABLE 163: Middle East Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 164: Middle East Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 165: Middle East 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 166: Middle East Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 167: Middle East Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 168: Middle East 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
IRAN
TABLE 169: Iran Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 170: Iran Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 171: Iran 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 172: Iran Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 173: Iran Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 174: Iran 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
ISRAEL
TABLE 175: Israel Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 176: Israel Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 177: Israel 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 178: Israel Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 179: Israel Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 180: Israel 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
SAUDI ARABIA
TABLE 181: Saudi Arabia Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 182: Saudi Arabia Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 183: Saudi Arabia 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 184: Saudi Arabia Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 185: Saudi Arabia Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 186: Saudi Arabia 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
UNITED ARAB EMIRATES
TABLE 187: UAE Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 188: UAE Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 189: UAE 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 190: UAE Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 191: UAE Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 192: UAE 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
REST OF MIDDLE EAST
TABLE 193: Rest of Middle East Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 194: Rest of Middle East Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 195: Rest of Middle East 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 196: Rest of Middle East Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 197: Rest of Middle East Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 198: Rest of Middle East 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
AFRICA
TABLE 199: Africa Recent Past, Current & Future Analysis for Pen Needles by Type - Standard and Safety - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 200: Africa Historic Review for Pen Needles by Type - Standard and Safety Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 201: Africa 15-Year Perspective for Pen Needles by Type - Percentage Breakdown of Value Sales for Standard and Safety for the Years 2012, 2021 & 2027
TABLE 202: Africa Recent Past, Current & Future Analysis for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 203: Africa Historic Review for Pen Needles by Therapy - Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 204: Africa 15-Year Perspective for Pen Needles by Therapy - Percentage Breakdown of Value Sales for Insulin, Glucagon-Like Peptide-1 (GLP-1) and Other Therapies for the Years 2012, 2021 & 2027
IV. COMPETITION
Total Companies Profiled: 63

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings